Drug interactions in psoriasis: the pros and cons of combining topical psoriasis therapies.
Endzweig-Gribetz
Carin H
CH
Department of Dermatology, Mount Sinai School of Medicine, One Gustave Levy Place, New York, New York 10029, USA. SinaiDerm@aol.com
Brady
Christopher
C
Lynde
Charles
C
Sibbald
Debra
D
Lebwohl
Mark
M
D000287:Administration, Topical; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects; D000875:Anthralin / Q000008:administration & dosage / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D003033:Coal Tar / Q000008:administration & dosage / Q000009:adverse effects; D004339:Drug Compounding; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects; D011565:Psoriasis / Q000188:drug therapy*; D020156:Salicylic Acid / Q000008:administration & dosage / Q000009:adverse effects; D012176:Retinoids
D000305:Adrenal Cortex Hormones; D000875:Anthralin; D000893:Anti-Inflammatory Agents; D002117:Calcitriol; D003033:Coal Tar; D007641:Keratolytic Agents; D009539:Nicotinic Acids; D020156:Salicylic Acid; C055085:calcipotriene; C086827:tazarotene; D012176:Retinoids